Risk factors for isolation of low-level mupirocin-resistant versus -susceptible methicillin-resistant Staphylococcus aureus from patients in intensive care units

Journal of Infection

Volumn 54, Issue 4, 2007, Pages 337-342

  Park, Dae Won ^a   Kim, Min Ja ^a   Yang, Jin Ah ^a   Jeong, Hye Won ^a   Sohn, Jang Wook ^a   Chun, Byung Chul ^a  

^a Center for Environmental Toxico Genomics and Proteomics   (South Korea)

Author keywords

MRSA; Mupirocin; Piperacillin tazobactam; Resistance; Risk factors

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BACTERIAL PROTEIN; CEFEPIME; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; IMIPENEM; MACROLIDE; METICILLIN; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; VANCOMYCIN;

ANIMAL CELL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL INFECTION; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EXPOSURE; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PULSED FIELD GEL ELECTROPHORESIS; RISK ASSESSMENT; RISK FACTOR; SURGICAL PATIENT;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CEPHALOSPORINS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; INTENSIVE CARE UNITS; MALE; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUPIROCIN; PENICILLANIC ACID; PIPERACILLIN; QUINOLONES; RISK FACTORS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 33947148215     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.06.008     Document Type: Article

References (28)

1. Hill R.L., Duckworth G.J., and Casewell M.W. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. J Antimicrob Chemother 22 (1988) 377-384
2. Hudson I.R. The efficacy of intranasal mupirocin in the prevention of staphylococcal infections: a review of recent experience. J Hosp Infect 27 (1994) 81-98
3. Barrett S.P. The value of nasal mupirocin in containing an outbreak of methicillin-resistant Staphylococcus aureus in an orthopaedic unit. J Hosp Infect 15 (1990) 137-142
4. Perl T.M., Cullen J.J., Wenzel R.P., Zimmerman M.B., Pfaller M.A., Sheppar D., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346 (2002) 1871-1877
5. Kluytmans J.A., Mouton J.W., VandenBergh M.F., Manders M.J., Maat A.P., Wagenvoort J.H., et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 17 (1996) 780-785
6. Casewell M.W. The nose: an underestimated source of Staphylococcus aureus causing wound infection. J Hosp Infect 40 (1998) S3-S11
7. Girou E., Pujade G., Legrand P., Cizeau F., and Brun-Buisson C. Selective screening of carriers for control of methicillin-resistant Staphylococcus aureus (MRSA) in high-risk hospital areas with a high level of endemic MRSA. Clin Infect Dis 27 (1998) 543-550
8. Cookson B.D., Lacey R.W., Noble W.C., Reeves D.S., Wise R., and Redhead R.J. Mupirocin-resistant Staphylococcus aureus. Lancet 335 (1990) 1095-1096
9. Miller M.A., Dascal A., Portnoy J., and Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 17 (1996) 811-813
10. Cookson B.D. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J Antimicrob Chemother 41 (1998) 11-18
11. Gilbart J., Perry C.R., and Slocombe B. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother 37 (1993) 32-38
12. Schmitz F.J., Lindenlauf E., Hofmann B., Fluit A.C., Verhoef J., Heinz H.P., et al. The prevalence of low- and high-level mupirocin resistance in staphylococci from 19 European hospitals. J Antimicrob Chemother 42 (1998) 489-495
13. Fujimura S., and Watanabe A. Survey of high- and low-level mupirocin-resistant strains of methicillin-resistant Staphylococcus aureus in 15 Japanese hospitals. Chemotherapy 49 (2003) 36-38
14. Yun H.J., Lee S.W., Yoon G.M., Kim S.Y., Choi S., Lee Y.S., et al. Prevalence and mechanisms of low- and high-level mupirocin resistance in staphylococci isolated from a Korean hospital. J Antimicrob Chemother 51 (2003) 619-623
15. Harbarth S., Dharan S., Liassine N., Herrault P., Auckenthaler R., and Pittet D. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 43 (1999) 1412-1416
16. Walker E.S., Vasquez J.E., Dula R., Bullock H., and Sarubbi F.A. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?. Infect Control Hosp Epidemiol 24 (2003) 342-346
17. Decousser J.W., Pina P., Ghnassia J.C., Bedos J.P., and Allouch P.Y. First report of clinical and microbiological failure in the eradication of glycopeptide-intermediate methicillin-resistant Staphylococcus aureus carriage by mupirocin. Eur J Clin Microbiol Infect Dis 22 (2003) 318-319
18. Gales A.C., Andrade S.S., Sader H.S., and Jones R.N. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals: report from the SENTRY antimicrobial surveillance program. J Chemother 16 (2004) 323-328
19. Deyo R.A., Cherkin D.C., and Ciol M.A. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 45 (1992) 613-619
20. Performance standards for antimicrobial disk susceptibility tests. Approved Standard M2-M5 (1993), National Committee for Clinical Laboratory Standards, Villanova
21. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 5th ed. (2000), National Committee for Clinical Laboratory Standards, Wayne
22. Katayama Y., Ito T., and Hiramatsu K. A new class of genetic element, Staphylococcus cassette chromosome mec, encodes methicillin resistance in Staphylococcus aureus. Antimicrob Agents Chemother 44 (2000) 1549-1555
23. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., Persing D.H., et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 (1995) 2233-2239
24. Kim P.W., Harris A.D., Roghmann M.C., Morris Jr. J.G., Strinivasan A., and Perencevich E.N. Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible Citrobacter freundii in hospitalized patients. Antimicrob Agents Chemother 47 (2003) 2882-2887
25. Harris A.D., Perencevich E., Roghmann M.C., Morris G., Kaye K.S., and Johnson J.A. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 46 (2002) 854-858
26. Chow J.W., Fine M.J., Shlaes D.M., Quinn J.P., Hooper D.C., Johnson M.P., et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 115 (1991) 585-590
27. Harris A.D., Smith D., Johnson J.A., Bradham D.D., and Roghmann M.C. Risk factors for imipenem-resistant Pseudomonas aeruginosa among hospitalized patients. Clin Infect Dis 34 (2002) 340-345
28. Troillet N., Samore M.H., and Carmeli Y. Imipenem-resistant Pseudomonas aeruginosa: risk factors and antibiotic susceptibility patterns. Clin Infect Dis 25 (1997) 1094-1098